Details of the Drug

General Information of Drug (ID: DMWUIJE)

Drug Name
Tolmetin
Synonyms
Tolectin; Tolmetina; Tolmetine; Tolmetino; Tolmetinum; Tolmetina [DCIT]; MCN 2559; McN-2559; Tolectin (TN); Tolmetin Sodium, Dihydrate; Tolmetine [INN-French]; Tolmetino [INN-Spanish]; Tolmetinum [INN-Latin]; Tolmetin (USAN/INN); Tolmetin [USAN:BAN:INN]; Acido 1-metil-5-(p-tolnil)-pirrol-2-acetico; Acido 1-metil-5-(p-tolnil)-pirrol-2-acetico [Spanish]; 1-Methyl-5-(4-methylbenzoyl)-1H-pyrrole-2-acetic acid; 1-Methyl-5-(4-methylbenzoyl)-pyrrole-2-acetic acid; 1-Methyl-5-p-toluoylpyrrole-2-acetic acid; 2-[1-methyl-5-(4-methylbenzoyl)pyrrol-2-yl]acetic acid; 5-(p-Toluoyl)-1-methylpyrrole-2-acetic acid
Indication
Disease Entry ICD 11 Status REF
Osteoarthritis FA00-FA05 Approved [1]
Rheumatoid arthritis FA20 Approved [2]
Therapeutic Class
Antiinflammatory Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 257.279
Logarithm of the Partition Coefficient (xlogp) 2.8
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Bioavailability
95% of drug becomes completely available to its intended biological destination(s) [4]
Elimination
7% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 2 hours [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 116.6 micromolar/kg/day [6]
Water Solubility
The ability of drug to dissolve in water is measured as 0.22 mg/mL [3]
Chemical Identifiers
Formula
C15H15NO3
IUPAC Name
2-[1-methyl-5-(4-methylbenzoyl)pyrrol-2-yl]acetic acid
Canonical SMILES
CC1=CC=C(C=C1)C(=O)C2=CC=C(N2C)CC(=O)O
InChI
InChI=1S/C15H15NO3/c1-10-3-5-11(6-4-10)15(19)13-8-7-12(16(13)2)9-14(17)18/h3-8H,9H2,1-2H3,(H,17,18)
InChIKey
UPSPUYADGBWSHF-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
5509
ChEBI ID
CHEBI:71941
CAS Number
26171-23-3
DrugBank ID
DB00500
TTD ID
D09BHB
ACDINA ID
D00687
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prostaglandin G/H synthase 2 (COX-2) TTVKILB PGH2_HUMAN Inhibitor [7]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Albumin (ALB) OTVMM513 ALBU_HUMAN Protein Interaction/Cellular Processes [8]
HLA class I histocompatibility antigen, alpha chain E (HLA-E) OTX1CTFB HLAE_HUMAN Gene/Protein Processing [9]
HLA class II histocompatibility antigen, DQ beta 1 chain (HLA-DQB1) OTVVI3UI DQB1_HUMAN Gene/Protein Processing [9]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Osteoarthritis
ICD Disease Classification FA00-FA05
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Prostaglandin G/H synthase 2 (COX-2) DTT PTGS2 7.93E-04 -0.29 -0.34
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Tolmetin
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Sulfasalazine DMICA9H Moderate Increased risk of nephrotoxicity by the combination of Tolmetin and Sulfasalazine. Rheumatoid arthritis [FA20] [10]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Tolmetin and Leflunomide. Rheumatoid arthritis [FA20] [11]
Coadministration of a Drug Treating the Disease Different from Tolmetin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Tolmetin and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [12]
Repaglinide DM5SXUV Moderate Increased risk of hypoglycemia by the combination of Tolmetin and Repaglinide. Acute diabete complication [5A2Y] [13]
Glibenclamide DM8JXPZ Moderate Increased risk of hypoglycemia by the combination of Tolmetin and Glibenclamide. Acute diabete complication [5A2Y] [13]
Tolazamide DMIHRNA Moderate Increased risk of hypoglycemia by the combination of Tolmetin and Tolazamide. Acute diabete complication [5A2Y] [13]
Nateglinide DMLK2QH Moderate Increased risk of hypoglycemia by the combination of Tolmetin and Nateglinide. Acute diabete complication [5A2Y] [13]
Glipizide DMZA5PQ Moderate Increased risk of hypoglycemia by the combination of Tolmetin and Glipizide. Acute diabete complication [5A2Y] [13]
Inotersen DMJ93CT Major Increased risk of bleeding by the combination of Tolmetin and Inotersen. Amyloidosis [5D00] [14]
Cilostazol DMZMSCT Moderate Increased risk of bleeding by the combination of Tolmetin and Cilostazol. Arterial occlusive disease [BD40] [15]
Budesonide DMJIBAW Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Tolmetin and Budesonide. Asthma [CA23] [16]
Ofloxacin DM0VQN3 Moderate Additive CNS stimulant effects by the combination of Tolmetin and Ofloxacin. Bacterial infection [1A00-1C4Z] [17]
Kanamycin DM2DMPO Moderate Increased risk of nephrotoxicity by the combination of Tolmetin and Kanamycin. Bacterial infection [1A00-1C4Z] [18]
Ciprofloxacin XR DM2NLS9 Moderate Additive CNS depression effects by the combination of Tolmetin and Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [17]
Trovafloxacin DM6AN32 Moderate Additive CNS stimulant effects by the combination of Tolmetin and Trovafloxacin. Bacterial infection [1A00-1C4Z] [17]
Sparfloxacin DMB4HCT Moderate Additive CNS stimulant effects by the combination of Tolmetin and Sparfloxacin. Bacterial infection [1A00-1C4Z] [17]
Gemifloxacin DMHT34O Moderate Additive CNS depression effects by the combination of Tolmetin and Gemifloxacin. Bacterial infection [1A00-1C4Z] [17]
Norfloxacin DMIZ6W2 Moderate Additive CNS stimulant effects by the combination of Tolmetin and Norfloxacin. Bacterial infection [1A00-1C4Z] [17]
ABT-492 DMJFD2I Moderate Additive CNS depression effects by the combination of Tolmetin and ABT-492. Bacterial infection [1A00-1C4Z] [17]
Gentamicin DMKINJO Moderate Increased risk of nephrotoxicity by the combination of Tolmetin and Gentamicin. Bacterial infection [1A00-1C4Z] [18]
Netilmicin DMRD1QK Moderate Increased risk of nephrotoxicity by the combination of Tolmetin and Netilmicin. Bacterial infection [1A00-1C4Z] [18]
Levofloxacin DMS60RB Moderate Additive CNS stimulant effects by the combination of Tolmetin and Levofloxacin. Bacterial infection [1A00-1C4Z] [17]
Tobramycin DMUI0CH Moderate Increased risk of nephrotoxicity by the combination of Tolmetin and Tobramycin. Bacterial infection [1A00-1C4Z] [18]
Lomefloxacin DMVRH9C Moderate Additive CNS stimulant effects by the combination of Tolmetin and Lomefloxacin. Bacterial infection [1A00-1C4Z] [17]
Etidronic acid DM1XHYJ Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Tolmetin and Etidronic acid. Bone paget disease [FB85] [19]
Risedronate DM5FLTY Moderate Increased risk of nephrotoxicity by the combination of Tolmetin and Risedronate. Bone paget disease [FB85] [19]
Alendronate DMY2KX9 Moderate Increased risk of nephrotoxicity by the combination of Tolmetin and Alendronate. Bone paget disease [FB85] [19]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Tolmetin and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [20]
Iodipamide DMXIQYS Major Increased risk of nephrotoxicity by the combination of Tolmetin and Iodipamide. Cholelithiasis [DC11] [21]
Levomilnacipran DMV26S8 Moderate Increased risk of bleeding by the combination of Tolmetin and Levomilnacipran. Chronic pain [MG30] [22]
Regorafenib DMHSY1I Major Increased risk of bleeding by the combination of Tolmetin and Regorafenib. Colorectal cancer [2B91] [14]
Oxaliplatin DMQNWRD Moderate Decreased renal excretion of Tolmetin caused by Oxaliplatin mediated nephrotoxicity. Colorectal cancer [2B91] [23]
Drospirenone DM1A9W3 Moderate Increased risk of hyperkalemia by the combination of Tolmetin and Drospirenone. Contraceptive management [QA21] [24]
Ardeparin DMYRX8B Major Increased risk of bleeding by the combination of Tolmetin and Ardeparin. Coronary thrombosis [BA43] [25]
Danaparoid DM6CLBN Major Increased risk of bleeding by the combination of Tolmetin and Danaparoid. Deep vein thrombosis [BD71] [25]
Rivaroxaban DMQMBZ1 Major Increased risk of bleeding by the combination of Tolmetin and Rivaroxaban. Deep vein thrombosis [BD71] [26]
Sertraline DM0FB1J Moderate Increased risk of bleeding by the combination of Tolmetin and Sertraline. Depression [6A70-6A7Z] [22]
Vilazodone DM4LECQ Moderate Increased risk of bleeding by the combination of Tolmetin and Vilazodone. Depression [6A70-6A7Z] [22]
Paroxetine DM5PVQE Moderate Increased risk of bleeding by the combination of Tolmetin and Paroxetine. Depression [6A70-6A7Z] [22]
Vortioxetine DM6F1PU Moderate Increased risk of bleeding by the combination of Tolmetin and Vortioxetine. Depression [6A70-6A7Z] [22]
Milnacipran DMBFE74 Moderate Increased risk of bleeding by the combination of Tolmetin and Milnacipran. Depression [6A70-6A7Z] [22]
Escitalopram DMFK9HG Moderate Increased risk of bleeding by the combination of Tolmetin and Escitalopram. Depression [6A70-6A7Z] [22]
Desvenlafaxine DMHD4PE Moderate Increased risk of bleeding by the combination of Tolmetin and Desvenlafaxine. Depression [6A70-6A7Z] [22]
Clomipramine DMINRKW Moderate Increased risk of bleeding by the combination of Tolmetin and Clomipramine. Depression [6A70-6A7Z] [22]
PMID28870136-Compound-49 DMTUC9E Moderate Increased risk of bleeding by the combination of Tolmetin and PMID28870136-Compound-49. Discovery agent [N.A.] [27]
Fenfluramine DM0762O Moderate Increased risk of bleeding by the combination of Tolmetin and Fenfluramine. Epilepsy/seizure [8A61-8A6Z] [22]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Tolmetin and Cannabidiol. Epileptic encephalopathy [8A62] [14]
Ethacrynic acid DM60QMR Moderate Antagonize the effect of Tolmetin when combined with Ethacrynic acid. Essential hypertension [BA00] [28]
Benzthiazide DMQWZ0H Moderate Antagonize the effect of Tolmetin when combined with Benzthiazide. Essential hypertension [BA00] [28]
Avapritinib DMK2GZX Major Increased risk of bleeding by the combination of Tolmetin and Avapritinib. Gastrointestinal stromal tumour [2B5B] [14]
Sulfinpyrazone DMEV954 Moderate Increased risk of bleeding by the combination of Tolmetin and Sulfinpyrazone. Gout [FA25] [15]
Eplerenone DMF0NQR Moderate Antagonize the effect of Tolmetin when combined with Eplerenone. Heart failure [BD10-BD1Z] [29]
Chlorothiazide DMLHESP Moderate Antagonize the effect of Tolmetin when combined with Chlorothiazide. Heart failure [BD10-BD1Z] [28]
Furosemide DMMQ8ZG Moderate Antagonize the effect of Tolmetin when combined with Furosemide. Heart failure [BD10-BD1Z] [28]
Amiloride DMRTSGP Moderate Antagonize the effect of Tolmetin when combined with Amiloride. Heart failure [BD10-BD1Z] [28]
Bumetanide DMRV7H0 Moderate Antagonize the effect of Tolmetin when combined with Bumetanide. Heart failure [BD10-BD1Z] [28]
Hydroflumethiazide DMVPUQI Moderate Antagonize the effect of Tolmetin when combined with Hydroflumethiazide. Heart failure [BD10-BD1Z] [28]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Tolmetin and Brentuximab vedotin. Hodgkin lymphoma [2B30] [30]
Efavirenz DMC0GSJ Moderate Increased risk of hepatotoxicity by the combination of Tolmetin and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [31]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Tolmetin and Mipomersen. Hyper-lipoproteinaemia [5C80] [32]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Tolmetin and Teriflunomide. Hyper-lipoproteinaemia [5C80] [11]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Tolmetin and BMS-201038. Hyper-lipoproteinaemia [5C80] [33]
Indapamide DMGN1PW Moderate Antagonize the effect of Tolmetin when combined with Indapamide. Hypertension [BA00-BA04] [28]
Trichlormethiazide DMHAQCO Moderate Antagonize the effect of Tolmetin when combined with Trichlormethiazide. Hypertension [BA00-BA04] [28]
Hydrochlorothiazide DMUSZHD Moderate Antagonize the effect of Tolmetin when combined with Hydrochlorothiazide. Hypertension [BA00-BA04] [34]
Dipyridamole DMXY30O Moderate Increased risk of bleeding by the combination of Tolmetin and Dipyridamole. Hypertension [BA00-BA04] [15]
Potassium chloride DMMTAJC Moderate Increased risk of hyperkalemia by the combination of Tolmetin and Potassium chloride. Hypo-kalaemia [5C77] [35]
Fludrocortisone DMUDIR8 Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Tolmetin and Fludrocortisone. Hypo-osmolality/hyponatraemia [5C72] [16]
Balsalazide DM7I1T9 Moderate Increased risk of nephrotoxicity by the combination of Tolmetin and Balsalazide. Indeterminate colitis [DD72] [10]
Methotrexate DM2TEOL Major Increased risk of nephrotoxicity by the combination of Tolmetin and Methotrexate. Leukaemia [2A60-2B33] [36]
Calaspargase pegol DMQZBXI Moderate Increased risk of bleeding by the combination of Tolmetin and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [37]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Tolmetin and Idelalisib. Mature B-cell leukaemia [2A82] [38]
Acalabrutinib DM7GCVW Major Increased risk of bleeding by the combination of Tolmetin and Acalabrutinib. Mature B-cell lymphoma [2A85] [39]
Clofarabine DMCVJ86 Moderate Increased risk of hepatotoxicity by the combination of Tolmetin and Clofarabine. Mature B-cell lymphoma [2A85] [14]
Ibrutinib DMHZCPO Major Increased risk of bleeding by the combination of Tolmetin and Ibrutinib. Mature B-cell lymphoma [2A85] [40]
Ponatinib DMYGJQO Major Increased risk of bleeding by the combination of Tolmetin and Ponatinib. Mature B-cell lymphoma [2A85] [41]
Exjade DMHPRWG Major Increased risk of nephrotoxicity by the combination of Tolmetin and Exjade. Mineral absorption/transport disorder [5C64] [42]
Panobinostat DM58WKG Major Increased risk of bleeding by the combination of Tolmetin and Panobinostat. Multiple myeloma [2A83] [12]
Deflazacort DMV0RNS Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Tolmetin and Deflazacort. Muscular dystrophy [8C70] [16]
Ruxolitinib DM7Q98D Moderate Increased risk of bleeding by the combination of Tolmetin and Ruxolitinib. Myeloproliferative neoplasm [2A20] [15]
Dasatinib DMJV2EK Major Increased risk of bleeding by the combination of Tolmetin and Dasatinib. Myeloproliferative neoplasm [2A20] [43]
Omacetaxine mepesuccinate DMPU2WX Major Increased risk of bleeding by the combination of Tolmetin and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [44]
Prasugrel DM7MT6E Major Increased risk of bleeding by the combination of Tolmetin and Prasugrel. Myocardial infarction [BA41-BA43] [14]
Vorapaxar DMA16BR Major Increased risk of bleeding by the combination of Tolmetin and Vorapaxar. Myocardial infarction [BA41-BA43] [45]
Tirofiban DMQG17S Moderate Increased risk of bleeding by the combination of Tolmetin and Tirofiban. Myocardial infarction [BA41-BA43] [46]
Sibutramine DMFJTDI Moderate Increased risk of bleeding by the combination of Tolmetin and Sibutramine. Obesity [5B80-5B81] [22]
Dexfenfluramine DMJ7YDS Moderate Increased risk of bleeding by the combination of Tolmetin and Dexfenfluramine. Obesity [5B80-5B81] [22]
Metolazone DMB39LO Moderate Antagonize the effect of Tolmetin when combined with Metolazone. Oedema [MG29] [28]
Polythiazide DMCH80F Moderate Antagonize the effect of Tolmetin when combined with Polythiazide. Oedema [MG29] [28]
Diclofenac DMPIHLS Moderate Increased risk of hepatotoxicity by the combination of Tolmetin and Diclofenac. Osteoarthritis [FA00-FA05] [47]
MK-4827 DMLYGH4 Moderate Increased risk of bleeding by the combination of Tolmetin and MK-4827. Ovarian cancer [2C73] [14]
Aspirin DM672AH Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Tolmetin and Aspirin. Pain [MG30-MG3Z] [48]
Prednisone DM2HG4X Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Tolmetin and Prednisone. Postoperative inflammation [1A00-CA43] [16]
Hydrocortisone DMGEMB7 Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Tolmetin and Hydrocortisone. Postoperative inflammation [1A00-CA43] [16]
Epoprostenol DMUTYR2 Moderate Increased risk of bleeding by the combination of Tolmetin and Epoprostenol. Pulmonary hypertension [BB01] [49]
Iloprost DMVPZBE Moderate Increased risk of bleeding by the combination of Tolmetin and Iloprost. Pulmonary hypertension [BB01] [49]
Everolimus DM8X2EH Major Increased risk of nephrotoxicity by the combination of Tolmetin and Everolimus. Renal cell carcinoma [2C90] [50]
Temsirolimus DMS104F Major Increased risk of nephrotoxicity by the combination of Tolmetin and Temsirolimus. Renal cell carcinoma [2C90] [50]
Gatifloxacin DMSL679 Moderate Additive CNS stimulant effects by the combination of Tolmetin and Gatifloxacin. Respiratory infection [CA07-CA4Z] [17]
Methylprednisolone DM4BDON Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Tolmetin and Methylprednisolone. Solid tumour/cancer [2A00-2F9Z] [16]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Tolmetin and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [14]
Prednisolone DMQ8FR2 Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Tolmetin and Prednisolone. Solid tumour/cancer [2A00-2F9Z] [16]
Pitolisant DM8RFNJ Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Tolmetin and Pitolisant. Somnolence [MG42] [14]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Tolmetin and Naltrexone. Substance abuse [6C40] [51]
Caplacizumab DMPUKA7 Moderate Increased risk of bleeding by the combination of Tolmetin and Caplacizumab. Thrombocytopenia [3B64] [15]
Apixaban DM89JLN Major Increased risk of bleeding by the combination of Tolmetin and Apixaban. Thrombosis [DB61-GB90] [14]
Cangrelor DM8JRH0 Moderate Increased risk of bleeding by the combination of Tolmetin and Cangrelor. Thrombosis [DB61-GB90] [15]
Brilinta DMBR01X Moderate Increased risk of bleeding by the combination of Tolmetin and Brilinta. Thrombosis [DB61-GB90] [14]
Cabozantinib DMIYDT4 Major Increased risk of bleeding by the combination of Tolmetin and Cabozantinib. Thyroid cancer [2D10] [52]
Sirolimus DMGW1ID Major Increased risk of nephrotoxicity by the combination of Tolmetin and Sirolimus. Transplant rejection [NE84] [50]
Tacrolimus DMZ7XNQ Major Increased risk of nephrotoxicity by the combination of Tolmetin and Tacrolimus. Transplant rejection [NE84] [50]
Tolbutamide DM02AWV Moderate Increased risk of hypoglycemia by the combination of Tolmetin and Tolbutamide. Type 2 diabetes mellitus [5A11] [13]
Chlorpropamide DMPHZQE Moderate Increased risk of hypoglycemia by the combination of Tolmetin and Chlorpropamide. Type 2 diabetes mellitus [5A11] [13]
Olsalazine DMZW9HA Moderate Increased risk of nephrotoxicity by the combination of Tolmetin and Olsalazine. Ulcerative colitis [DD71] [10]
Cinoxacin DM4EWNS Moderate Additive CNS stimulant effects by the combination of Tolmetin and Cinoxacin. Urinary tract infection [GC08] [17]
Plazomicin DMKMBES Moderate Increased risk of nephrotoxicity by the combination of Tolmetin and Plazomicin. Urinary tract infection [GC08] [18]
Nalidixic acid DMRM0JV Moderate Additive CNS stimulant effects by the combination of Tolmetin and Nalidixic acid. Urinary tract infection [GC08] [17]
Triamcinolone DM98IXF Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Tolmetin and Triamcinolone. Vasomotor/allergic rhinitis [CA08] [16]
Betrixaban DM2C4RF Major Increased risk of bleeding by the combination of Tolmetin and Betrixaban. Venous thromboembolism [BD72] [53]
⏷ Show the Full List of 117 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
Erythrosine sodium anhydrous E00324 27872 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF E00255 17730 Colorant
Carmellose sodium E00625 Not Available Disintegrant
Crospovidone E00626 Not Available Disintegrant
FD&C red no. 3 E00629 Not Available Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Gelatin E00630 Not Available Other agent
Hypromellose E00634 Not Available Coating agent
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
Pregelatinized starch E00674 Not Available Binding agent; Diluent; Disintegrant
⏷ Show the Full List of 24 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Tolmetin 400 mg capsule 400 mg Oral Capsule Oral
Tolmetin 600 mg tablet 600 mg Oral Tablet Oral
Tolmetin Sodium eq 600mg base tablet eq 600mg base Tablet Oral
Tolmetin Sodium eq 400mg base capsule eq 400mg base Capsule Oral
Tolmetin 200 mg tablet 200 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Tolmetin FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7311).
3 BDDCS applied to over 900 drugs
4 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Maternal toxicity of nonsteroidal anti-inflammatory drugs as an important factor affecting prenatal development. Reprod Toxicol. 2009 Sep;28(2):239-44.
8 Reversible binding of tolmetin, zomepirac, and their glucuronide conjugates to human serum albumin and plasma. J Pharmacokinet Biopharm. 1994 Feb;22(1):19-40. doi: 10.1007/BF02353408.
9 Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
10 Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442. [PMID: 3132281]
11 EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions.".
12 Cerner Multum, Inc. "Australian Product Information.".
13 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
14 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
15 Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
16 Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6. [PMID: 8724264]
17 Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
18 Assael BM, Chiabrando C, Gagliardi L, Noseda A, Bamonte F, Salmona M "Prostaglandins and aminoglycoside nephrotoxicity." Toxicol Appl Pharmacol 78 (1985): 386-94. [PMID: 4049389]
19 Product Information. Actonel (risedronate). Procter and Gamble Pharmaceuticals, Cincinnati, OH.
20 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
21 Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
22 Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
23 Product Information. Eloxatin (oxaliplatin). Sanofi Winthrop Pharmaceuticals, New York, NY.
24 Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
25 Bang CJ, Riedel B, Talstad I, Berstad A "Interaction between heparin and acetylsalicylic acid on gastric mucosal and skin bleeding in humans." Scand J Gastroenterol 27 (1992): 489-94. [PMID: 1321488]
26 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
27 Canadian Pharmacists Association.
28 Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV "Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers." Eur J Clin Pharmacol 48 (1995): 247-51. [PMID: 7589049]
29 Abdel-Haq B, Magagna A, Favilla S, Salvetti A "Hemodynamic and humoral interactions between perindopril and indomethacin in essential hypertensive subjects." J Cardiovasc Pharmacol 18 (1991): s33-6. [PMID: 1725198]
30 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
31 Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
32 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
33 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
34 McCarthy JT, Torres VE, Romero JC, et al "Acute intrinsic renal failure induced by indomethacin." Mayo Clin Proc 57 (1982): 289-96. [PMID: 6952058]
35 Product Information. Potassium Chloride ER (potassium chloride). Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.
36 Adams JD, Hunter GA "Drug interaction in psoriasis." Australas J Dermatol 17 (1976): 39-40. [PMID: 1022213]
37 Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
38 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
39 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
40 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
41 Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
42 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
43 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
44 Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
45 Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.
46 Product Information. Integrilin (eptifibatide). Schering Laboratories, Kenilworth, NJ.
47 Product Information. Solaraze (diclofenac topical). Doak Dermatologics Division, Fairfield, NJ.
48 Abdel-Rahman MS, Reddi AS, Curro FA, Turkall RM, Kadry AM, Hansrote JA "Bioavailability of aspirin and salicylamide following oral co-administration in human volunteers." Can J Physiol Pharmacol 69 (1991): 1436-42. [PMID: 1777842]
49 Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.
50 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
51 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
52 Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
53 Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.